Regeneron Pharmaceuticals Deferred Revenue increased by 15.0% to $636.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.7%, from $619.30M to $636.20M. Over 5 years (FY 2020 to FY 2025), Deferred Revenue shows relatively stable performance with a -0.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests strong sales of subscription-based services or bundled offerings, providing a predictable pipeline for future revenue recognition.
Represents cash payments received from customers in advance of the company fulfilling its performance obligations, speci...
High-growth software and services companies typically maintain larger deferred revenue balances relative to pure hardware manufacturers.
deferred_revenue_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $520.00M | $507.80M | $442.00M | $491.30M | $566.30M | $547.20M | $477.90M | $426.30M | $381.10M | $417.30M | $458.90M | $516.70M | $586.00M | $627.20M | $627.70M | $619.30M | $481.90M | $545.60M | $553.00M | $636.20M |
| QoQ Change | — | -2.3% | -13.0% | +11.2% | +15.3% | -3.4% | -12.7% | -10.8% | -10.6% | +9.5% | +10.0% | +12.6% | +13.4% | +7.0% | +0.1% | -1.3% | -22.2% | +13.2% | +1.4% | +15.0% |
| YoY Change | — | — | — | — | +8.9% | +7.8% | +8.1% | -13.2% | -32.7% | -23.7% | -4.0% | +21.2% | +53.8% | +50.3% | +36.8% | +19.9% | -17.8% | -13.0% | -11.9% | +2.7% |